These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32447102)

  • 1. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.
    Marfella R; Paolisso P; Sardu C; Bergamaschi L; D'Angelo EC; Barbieri M; Rizzo MR; Messina V; Maggi P; Coppola N; Pizzi C; Biffi M; Viale P; Galié N; Paolisso G
    Diabetes Metab; 2020 Oct; 46(5):403-405. PubMed ID: 32447102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
    Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
    Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
    Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
    J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
    Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
    Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
    Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
    Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Balblanc JC; Badie J; Royer PY; Toko L; Mezher C; Kadiane-Oussou NJ; Bossert M; Bozgan AM; Charpentier A; Roux MF; Contreras R; Mazurier I; Dussert P; Gendrin V; Conrozier T;
    Med Mal Infect; 2020 Aug; 50(5):397-400. PubMed ID: 32387320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
    Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
    Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate use of tocilizumab in COVID-19 infection.
    Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
    Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?
    Sardu C; D'Onofrio N; Balestrieri ML; Barbieri M; Rizzo MR; Messina V; Maggi P; Coppola N; Paolisso G; Marfella R
    Diabetes Care; 2020 Jul; 43(7):1408-1415. PubMed ID: 32430456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration.
    Fadini GP; Morieri ML; Boscari F; Fioretto P; Maran A; Busetto L; Bonora BM; Selmin E; Arcidiacono G; Pinelli S; Farnia F; Falaguasta D; Russo L; Voltan G; Mazzocut S; Costantini G; Ghirardini F; Tresso S; Cattelan AM; Vianello A; Avogaro A; Vettor R
    Diabetes Res Clin Pract; 2020 Oct; 168():108374. PubMed ID: 32805345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Selles P; Zahra H; Kadiane-Oussou NJ; Toko L; Royer PY; Balblanc JC; Gendrin V; Conrozier T;
    Int J Infect Dis; 2020 Oct; 99():491-495. PubMed ID: 32798660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19.
    Sardu C; Gargiulo G; Esposito G; Paolisso G; Marfella R
    Cardiovasc Diabetol; 2020 Jun; 19(1):76. PubMed ID: 32527257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease 2019.
    Zhang J; Kong W; Xia P; Xu Y; Li L; Li Q; Yang L; Wei Q; Wang H; Li H; Zheng J; Sun H; Xia W; Liu G; Zhong X; Qiu K; Li Y; Wang H; Wang Y; Song X; Liu H; Xiong S; Liu Y; Cui Z; Hu Y; Chen L; Pan A; Zeng T
    Front Endocrinol (Lausanne); 2020; 11():525. PubMed ID: 32754119
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
    Smetana K; Brábek J
    In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. May IL-17 have a role in COVID-19 infection?
    Megna M; Napolitano M; Fabbrocini G
    Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777
    [No Abstract]   [Full Text] [Related]  

  • 19. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
    Sciascia S; Aprà F; Baffa A; Baldovino S; Boaro D; Boero R; Bonora S; Calcagno A; Cecchi I; Cinnirella G; Converso M; Cozzi M; Crosasso P; De Iaco F; Di Perri G; Eandi M; Fenoglio R; Giusti M; Imperiale D; Imperiale G; Livigni S; Manno E; Massara C; Milone V; Natale G; Navarra M; Oddone V; Osella S; Piccioni P; Radin M; Roccatello D; Rossi D
    Clin Exp Rheumatol; 2020; 38(3):529-532. PubMed ID: 32359035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
    Berlot G; Tomasini A; Roman Pognuz E; Randino A; Chiella F; La Fata C; Piva M; Amato P; di Maso V; Bianco F; Gerini U; Tomietto P; Trenti T
    Nephron; 2020; 144(9):459-462. PubMed ID: 32694244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.